Table 4 Univariate and multivariate analysis of progression-free survival in T790M+ NSCLC patients with osimertinib treatment (PFS2) (n = 151).

From: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

Characteristics

HR (95% CI)a

P value

Adjusted HR (95% CI)a

P value

Age

< 65

Reference

   

≥ 65

0.78 (0.53–1.15)

0.213

  

Sex

Male

Reference

   

Female

0.87 (0.58–1.29)

0.478

  

Smoking status

NS

Reference

   

C/FS

1.59 (0.95–2.65)

0.079

  

ECOG PS

    

2–4

Reference

   

0–1

0.52 (0.30–0.90)

0.019

0.51 (0.29–0.90)

0.020

CNS metastasis

Yes

Reference

   

No

0.87 (0.59–1.28)

0.483

  

Baseline EGFR mutation status

L858R

Reference

   

19Del

0.93 (0.63–1.36)

0.709

  

1st line EGFR-TKI

Afatinib

Reference

   

Gefitinib

0.66 (0.31–1.40)

0.279

  

Erlotinib

0.73 (0.35–1.55)

0.416

  
  1. NSCLC non-small-cell lung cancer, HR hazard ratio, CI confidence interval, NS non-smoker, C/FS current/former-smoker, ECOG PS Eastern Cooperative Oncology Group performance status, CNS central nervous system, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor.
  2. aBy Cox proportional hazard model.
Back to article page